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Abstract
Introduction
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly spread throughout the world with a large medical and economic impact. On March 12,
2020, the World Health Organization (WHO) classified SARS-CoV-2 as a pandemic. As a result of
this worldwide public health crisis, politicians, elected officials, and healthcare professionals
emergently began trialing hydroxychloroquine (HCQ) in efforts to treat and prevent the
transmission of the virus. This meta-analysis was performed to assess the effects of HCQ on
patients with COVID-19.

Methods
This meta-analysis adheres to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRIMA) guidelines. Selected articles published between December 2019 and July 2020
were found utilizing the following search engines: PubMed, Google Scholar, Cochrane Library,
DisasterLit, Clinicaltrials.gov, Medrxiv, and Embase. Two independent physician reviewers
screened eligible articles that met the inclusion and exclusion criteria of the analysis. The
outcome measures analyzed were mortality rate, rate of disease progression/improvement, rate
of disease severity, and adverse effects of treatment. Six out of 14 studies that met the study’s
eligibility criteria were selected and further analyzed, with a total of 381 participants (n= 381).

Conclusion
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From the studies analyzed, it was found that groups treated with HCQ had an overall mortality
rate that was 2.5 times greater than that of the control group. HCQ treated patients had higher
rates of adverse clinical outcomes and side effects compared with the control
populations. Lastly, there was a 1.2 times higher rate of improvement in the group of HCQ
treated patients with mild to moderate symptoms as compared to the control group.

Review ended 08/13/2020
Published 08/24/2020
© Copyright 2020
Hussain et al. This is an open access
article distributed under the terms of

Categories: Internal Medicine, Infectious Disease, Public Health
Keywords: hydroxychloroquine, chloroquine, azithromycin, covid-19, coronavirus, sars-cov-2

the Creative Commons Attribution
License CC-BY 4.0., which permits
unrestricted use, distribution, and
reproduction in any medium, provided
the original author and source are
credited.

Introduction
Coronavirus disease (COVID-19) originated in Wuhan, Hubei Province of China on December 15,
2019 [1-4]. The rapid spread of the virus led the World Health Organization (WHO) to announce
COVID-19 as a pandemic on March 12, 2020 [5]. The spread of SARS-CoV-2 resulted in an
enormous public health crisis with high patient mortality and significant economic
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consequences [1,6]. Furthermore, COVID-19 is a complex, multifaceted, multi-system disease
process that spares no one [7].
The COVID-19 acute respiratory distress syndrome consists of a period of cytokine storm, which
is noted particularly in the later stages of advanced severe respiratory failure [8]. COVID-19
patients have increased levels of plasma pro-inflammatory cytokines and chemokines [9-10].
These cytokines and chemokines are IL1b, IL1RA, IL7, IL8, IL9, IL10, basic FGF2, GCSF, GMCSF,
IFNg, IP10, MCP1, MIP1a, MIP1b, PDGFB, TNFa, and VEGFA [9-10]. High patient mortality is
caused by the disarray of these host cytokines, causing damage to the lungs and leading to
multi-system organ failure [10-11].
The SARS-CoV-2 virus has an affinity for the ciliated cells of the respiratory conducting airway,
with increased viral replication as it progresses further along the respiratory tract and
gastrointestinal mucosa [12]. The SARS CoV-2 infection occurs in three distinct stages: an
asymptomatic stage, an upper airway stage, and, finally, the conducting airway response stage,
which leads to the classically seen ground-glass infiltrates on chest X-ray and clinical hypoxia
with progression to acute respiratory distress syndrome (ARDS) and multi-system dysfunction
[13]. In stage 1, the virus binds to the angiotensin-converting enzyme 2 (ACE2) receptor, a
transmembrane protease, serine 2 (TMPRSS2). TMPRSS2 is ubiquitous in the human body; it is
found in the nasal cavity and lung and is also expressed throughout the intestine and prostate
[14]. ACE2 receptors can also be found in the heart, esophagus, kidneys, stomach, bladder, and
ileum [12,14]. As SARS-CoV-2 progresses down the respiratory tract, the virus begins to activate
a more potent immune response and certain patients may manifest clinically with respiratory
failure and ARDS.
Most patients will have a mild disease, with the disease restricted to the upper respiratory tract
[13]. About one out of five SAR-CoV-2 infected patients will progress to more severe respiratory
disease and further to ARDS [13]. The proposed mechanism is the destruction of type II
pneumocytes once the virus reaches the alveoli [12]. The virus would then begin the replication
process within these cells and the cell would undergo apoptosis, releasing viral particles. This
cellular apoptosis results in diffuse alveolar damage with the formation of hyaline membranes,
which decrease gas exchange and lead to clinical hypoxia. Furthermore, the healing of the
affected areas may worsen the patient’s condition through more severe parenchymal scarring
and fibrosis. Because the cytokines mentioned above have binding sites within the lungs, they
may serve as therapeutic targets.
4-Aminoquinolones such as hydroxychloroquine (HCQ) and chloroquine have gained a lot of
steam in the medical field and media for their possible efficacy against COVID-19. HCQ has
immunomodulatory properties and was originally developed as an antimalarial drug with further
applications in patients with rheumatoid arthritis and systemic lupus erythematosus [15]. In
vitro studies of HCQ have additionally shown antiviral properties; it supposedly prevents
COVID-19 related ARDS [8,15-16]. The treatment of COVID-19 positive patients with HCQ has
been met with controversy, as there have been no large multicenter randomized control trials to
support its use. Up to this point, there is a lack of statistically significant reduction in morbidity
or mortality in COVID-19 patients who have undergone HCQ trials.
The treatment of COVID-19 with a combination of hydroxychloroquine and azithromycin was
first proposed in a controversial, small non-randomized trial from the South of France that
concluded that the drug combination was effective for the treatment of COVID-19 [17]. Criticism
was brought on immediately when it was presented for peer review due to many methodological
flaws, with the biggest being the lack of a randomized control group [17]. This led to various
expert researchers criticizing the efficacy of hydroxychloroquine, with the majority concluding
no statistically significant difference between treatment groups.
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The emergent approval of HCQ at the height of the COVID-19 pandemic was considered
controversial but necessary given the overwhelming lack of effective treatment options at that
time. The controversy was limited not only to the unknown efficacy and side-effect profile of
HCQ but also to the limited supply of the drug [18].

Materials And Methods
This systematic review and meta-analysis adheres to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Figure 1) [2]. The search terms
used were hydroxychloroquine, chloroquine, azithromycin, COVID-19, coronavirus, and SARSCoV-2. Using these terms, the systematic search strategies used were boolean and fuzzy logic,
truncated terms, and wild cards. Selected articles published between December 2019 and July
2020 were found utilizing the following search engines: PubMed, Google Scholar, Cochrane
Library, DisasterLit, Clinicaltrials.gov, Medrxiv, and Embase. Two independent physician
reviewers screened eligible articles that met the analysis’ inclusion and exclusion criteria. The
inclusion criteria were (1) age range 12-65, (2) prospective control trial, and (3) use of
hydroxychloroquine, chloroquine, lopinavir-ritonavir, or azithromycin. The exclusion criteria
were (1) presence of a co-morbid medical condition, i.e., advanced heart, liver, or renal
disease or diabetes mellitus, (2) treatment with remdesivir, convalescent plasma,
corticosteroids, vaccines, IL-6 inhibitors, T-cell therapy, α-ketoamide inhibitors, resiniferatoxin,
teicoplanin, favipiravir, extracorporeal therapy, or HCQ prophylaxis.
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FIGURE 1: PRISMA flow diagram
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

The outcome measures analyzed were HCQ’s effect on COVID-19 mortality rate, rate of disease
progression/rate of improvement, rate of disease severity, and adverse effects of treatment. Six
out of 14 studies that met the study’s eligibility criteria were selected and further analyzed, with
a total of 381 participants (n= 381).
Data collected from six different studies looked at the effects of HCQ on patients with clinically
proven COVID-19 infection. These six studies have been labeled S1, S2, S3, S4, S5, and S6 for
better data visualization. Each study varies in sample sizes and the distribution of treatment and
control groups. The defined outcomes studied in this meta-analysis are:
1) The mortality rate of patients after applying HCQ on patients with COVID-19
2) The rate of progression/improvement of COVID-19 disease

2020 Hussain et al. Cureus 12(8): e10005. DOI 10.7759/cureus.10005

4 of 17

3) The rate of COVID-19 disease severity, for example, after applying the HCQ treatment, the
rate of which patients went on to develop severe conditions such as acute hypoxic respiratory
failure and adult respiratory distress syndrome.
The random-effects model was used on the assumption that the study effect estimates show
more variance when drawn from a single population [19]. Therefore, this follows the so-called
assumption of exchangeability [19]. This means that in a random-effects model fit, not only do
assumptions of the effects of individual studies deviate from the true intervention effect of all
studies due to sampling error but that there is another source of variance introduced by the fact
that the studies do not stem from one single population [19]. The studies are sampled from a
“universe” of populations [19]. In this study, the random effect model is a suitable
choice because it is a risky assumption to state all the studies along with their respective effect
sizes stem from a single homogeneous population.

Results
Section A: meta-analysis on mortality rates
Among the six studies considered for meta-analysis, information on mortality rates was
available in two of them, details of which are provided below (Tables 1-3).

Name

Author

A pilot study of hydroxychloroquine in the treatment of

Chen J, et

patients with common coronavirus disease-19 (COVID-19)

al. [20]

Effect of high VS low doses of chloroquine diphosphate as
adjunctive therapy for patients hospitalized with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection: a randomized clinical trial.

Sample

num_

num_

mortality_

mortality_

Size

control

treatment

control

treatment

30

15

15

0

0

81

40

41

6

16

Borba,
Mayla
Gabriela
Silva, et al.
[21]

TABLE 1: Studies used in the meta-analysis of mortality rate

Estimate

Standard error

Z value

P-value

Lower bound

Upper bound

0.9324

0.4409

2.1148

0.0344

0.0683

1.7965

TABLE 2: Fitted random effect model
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Measure

Estimate

Lower Bound

Upper Bound

tau^2

0

0

>100.0000

tau

0

0

>10.0000

I^2(%)

0

0

>97.9720

H^2

1

1

>49.3097

TABLE 3: Heterogeneity measure

Here, the estimated average log relative risk is equal to ˆμ=0.9324 (95% CI: 0.0683 to 1.7965).
For easier interpretation, it may be useful to transform these values back to the relative risk scale
through exponentiation (i.e., exp(ˆμ) = 2.54 with 95% CI: 1.07 to 6.03). The interpretation of
these results, therefore, suggests that the risk of mortality in HCQ treated individuals is on
average 2.5 times greater than in non-HCQ individuals. The null hypothesis H0: μ= 0 can be
clearly rejected (p < 0.05).
These studies are perfectly homogeneous as tau^2 is 0 (equivalently, H^2 is 1). See Figures 2-3
for more information.

FIGURE 2: Disease mortality forest plot
Interpretation
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Study 1 has more uncertainty in its results as evident due to the wide spread of the horizontal line.
Studies 1 and 2 both do not cross the effect line at 0, indicating that they are not in agreement with
the mortality rate of HCQ treated COVID-19 positive patients.

FIGURE 3: Disease mortality funnel plot
Interpretation
There is a marginal asymmetry between the studies, however, as the number of studies is small, this
result can be attributed purely to chance rather than any actual publication bias.

Section B: meta-analysis on progression/improvement rates
Among the six studies considered for meta-analysis, information on disease progression rates
are available in four of them, details of which are provided below (Tables 4-6).
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Name

Author

A pilot study of hydroxychloroquine in the treatment of

Chen J,

patients with common coronavirus disease-19 (COVID

et al.

19)

[20]

Efficacy of hydroxychloroquine in patients with COVID-

Chen et

19 results of a randomized clinical trial

al. [22]

Sample

num_

num_

progression_

progression_

Size

control

treatment

control

treatment

30

15

15

7

5

62

31

31

17

25

22

12

10

11

10

36

16

20

0

20

Huang,
Treating COVID-19 with Chloroquine

et al.
[23]

Hydroxychloroquine and azithromycin as a treatment of

Gautret,

COVID-19 results of an open-label non- randomized

et al.

clinical trial

[17]

TABLE 4: Studies used in meta-analysis of improvement/progression rate

Estimate

Standard error

Z value

P-value

Lower bound

Upper bound

0.1839

0.2302

0.7987

0.4245

-0.2673

0.6351

TABLE 5: Fitted Random Effect Model

Measure

Estimate

Lower bound

Upper bound

tau^2

0.0495

0

48.0704

tau

0.2224

0

6.9333

I^2(%)

22.4095

0

99.6449

H^2

1.2888

1

281.598

TABLE 6: Heterogeneity measure

Here, the estimated average log relative risk is equal to ˆμ=0.1839 (95% CI: -0.2673 to 0.6351)
[4]. For easier interpretation, these values were transformed back to the relative risk scale
through exponentiation (i.e., exp(ˆμ) = 1.2019 with 95% CI: 0.77 to 1.89). The interpretation of
the results suggests that the disease progression rate in HCQ treated individuals is on average
1.2 times as large as the non-HCQ individuals. The null hypothesis H0: μ= 0 cannot be rejected
(p > 0.05).
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These studies are a bit heterogeneous, though by a very small amount. See Figures 4-5 for more
information.

FIGURE 4: Disease progression forest plot
Interpretation
Study 6 has more uncertainty in its results as evident by the width of the horizontal line [19]. All
studies, except Study 6, are in agreement with the results of a disease progression rate of HCQ
treatment in patients with COVID [19].
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FIGURE 5: Disease progression funnel plot
Interpretation
The studies are symmetric except Study 6, which falls outside the triangle. This is in line with the
conclusion drawn from the funnel plot. However, as evidenced by the funnel plot, Study 6 has very
low power and thus its effect can be ignored.

Section C: meta-analysis on severity rates
Among the six studies considered, information on disease severity rates are available in four, the
details of which are provided below (Tables 7-9).
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Name

Author

A pilot study of hydroxychloroquine in the
treatment of patients with common
coronavirus disease 19 (COVID-19)
Hydroxychloroquine in patients with
COVID-19: an open-label, randomized,
controlled trial
Treating COVID-19 with chloroquine

Chen J, et
al. [20]

Tang, et al.
[24]
Huang, et al.
[23]

Hydroxychloroquine: small effects in mild

Levantovsky,

disease

et al. [25]

Sample

num_

num_

severe_or

severe_or

Size

control

treatment

adverse_control

adverse_treatment

30

15

15

0

1

150

80

70

7

21

22

12

10

5

O

62

31

31

4

0

TABLE 7: Studies used in meta-analysis of severity rate

Estimate

Standard error

Z value

P-value

Lower bound

Upper bound

-0.3644

0.9996

-0.3645

0.7155

-2.3236

1.5949

TABLE 8: Fitted random effect model

Measure

Estimate

Lower bound

Upper bound

tau^2

2.4987

0

51.7919

tau

1.5807

0

7.1967

I^2(%)

65.7314

0

97.5465

H^2

2.9181

1

40.7582

TABLE 9: Heterogeneity measure

Here, the estimated average log relative risk is equal to ˆμ=-0.3644 (95% CI: -2.3236 to 1.5949)
[19]. For easier interpretation, these values are transformed back to the relative risk scale
through exponentiation (i.e., exp(ˆμ) = 0.6946 with 95% CI: 0.10 to 4.92). The interpretation of
these results suggests that the disease severity rate in HCQ treated individuals is on average
0.69 that of the non-HCQ individuals. The null hypothesis H0: μ= 0 can be rejected (p < 0.05).
These studies exhibit heterogeneity by a moderate amount. See Figures 6-7 for more
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information.

FIGURE 6: Disease severity forest plot
Interpretation
The results of all studies agree with the disease severity rate of HCQ treated COVID positive
patients. There is slight disagreement shown by Study 4 by a moderate amount.
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FIGURE 7: Disease severity funnel plot
Interpretation
The studies are symmetric except for Study 1, which falls on the border of the triangle. The remaining
three studies, however, show symmetry among them.

A summary of the meta-analyses' findings is provided in Table 10.
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Metaanalysis on

#
Studies

Random effect model conclusion

used

Heterogeneity

Conclusion

between

from the

studies

forest plot

A bit of

Progression/
Improvement

4

Rate

Progression rate in HCQ treated

heterogeneity

individuals is on average 1.2 times

is observed

than non-HCQ individuals. This

among

implies HCQ patients are slightly at

studies, which

an advantage on progression rate as

might be

compared to non-HCQ patients.

attributed to
Study 6.

All studies are
in agreement
except Study
6, which shows
some
uncertainty in
its results.

Conclusion from the funnel
plot

Study 6 has a bit of asymmetry,
implying a small publication
bias. It should be noted that
study 6 has very low power also
to distinguish the effect of HCQ
from non-HCQ treatment.

The severity rate in HCQ treated
Severity
Rate

4

individuals is on average 0.69 times

Slight

All studies are

the non HCQ individuals. This means

heterogeneity

in agreement

HCQ treated patients are 0.69 times

observed

with respect to

more likely to face severe situations

among studies

the conclusion.

Studies are symmetric except
Study 1, showing slight
asymmetry ie publication bias.

than non-HCQ patients.
Study 2 is

Mortality
Rate

2

No

more confident

The risk of mortality in HCQ treated

heterogeneity

about its

individuals is on average 2.54 times

found, i.e.,

results and

more than the non HCQ individuals.

studies are

Study 1 is

homogeneous

relatively less

Slight asymmetry is noticed,
however, as the number of
studies are only two, it can be
due to random effects.

confident.

TABLE 10: Summary table

Discussion
The side effects of 4-Aminoquinolones are known to be dose-dependent increased risks for
retinopathy, methemoglobinemia, and gastrointestinal (GI), renal, and cardiac toxicity
[26]. HCQ co-administered with medications such as AZT further increases the risk of toxicity,
particularly prolongation of the QT interval on electrocardiogram. The Borba et al. study
revealed that males aged 50 with severe COVID symptoms and heart disease are at high risk for
developing HCQ-related cardiac complications such as QT prolongation at higher doses of HCQ
[21]. This toxicity is especially noted when combined with AZT, which is known to prolong the
QT interval in populations with cardiac disease [21]. The studies by Tang et al. [24] and Chen J et
al. [20] showed greater HCQ-related GI side effects as well.
In a post-marketing study by the Food and Drug Administration (FDA), it was also shown that
the use of 4-Aminoquinolones increased rates of cardiac arrhythmias, ventricular tachycardia,
fibrillation, and torsades de pointes. Their analysis also noted adverse cardiac events in
combination with the use of other QT-prolonging medications such as azithromycin [27]. As a
result, the FDA has cautioned the use of HCQ in COVID-19 patients, especially outside of the
inpatient hospital setting [27]. Similarly, this meta-analysis supports that HCQ treated patients
are more likely to have adverse side effects. It also appears that treatment with HCQ has a
fatality rate of approximately 2.5 higher than with the control group.
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The non-randomized study performed by Gautret et al. in the South of France included a total of
36 young patients with positive PCR test results and milder COVID-19 disease with no advanced
comorbid medical conditions. A 50% reduction in viral load was noted at one week with a low
dose of HCQ with AZT [17]. This study was not powered to detect mortality outcomes. Similarly,
Yang et al. [19], Mingxing et al. [23], and Chen J et al. [20] studied females with a median age of
45 and mild COVID-19 related upper respiratory/pneumonia symptoms, without co-existing comorbid medical disease. Patients were stated to have improved time to clinical resolution in the
HCQ treatment arm [20,22-23]. These results seem to be in line with the meta-analysis’ of a
slight disease improvement in COVID-19 patients treated with HCQ as compared with the
controls.
Furthermore, recent studies show a gender disparity, in that females show better outcomes as
compared to similar male cohorts [14]. This gender disparity is seen in a recent study that noted
that male patients with advanced age or multiple comorbid medical conditions are at higher risk
for mortality [11,14]. The studies in this meta-analysis did not include these high-risk patients
with underlying complex co-morbid medical conditions, severe cases of COVID-19, ARDS, or
critical care patient populations.

Limitations
Of note, the studies included in this meta-analysis have various definitions of control groups,
which might affect the conclusion. However, with respect to the disease progression and severity
meta-analysis, it appears that most of the studies are in agreement with the results, with slight
exceptions, which might be attributed to chance. To get a more robust conclusion, the metaanalysis can be performed on more studies rather than six prospective control trials. Currently,
there are 107 HCQ clinical trials in the active recruitment phase [28]; as the pandemic continues
to unfold, these future large multicenter randomized controlled clinical trials may be included in
the meta-analysis to conclude the size effect of HCQ on COVID-19.

Conclusions
Our study looks at three disease outcome measures of treatment with HCQ in patients with
COVID-19: mortality rates, progression rates, and severity rates. In terms of mortality rates, it
appears treatment with HCQ has a fatality rate that is 2.5 times greater than that of the control
group. Similarly, HCQ treated patients are more likely to have an adverse clinical outcome and
side effects. Lastly, there was a 1.2-times higher rate of clinical improvement in the group of
HCQ treated patients, with mild to moderate symptoms as compared to the control group.

Additional Information
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subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form,
all authors declare the following: Payment/services info: All authors have declared that no
financial support was received from any organization for the submitted work. Financial
relationships: All authors have declared that they have no financial relationships at present or
within the previous three years with any organizations that might have an interest in the
submitted work. Other relationships: All authors have declared that there are no other
relationships or activities that could appear to have influenced the submitted work.
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